EC approves Xgeva for MM patients

Amgen Inc. (NASDAQ:AMGN) said the European Commission approved a label expansion for Xgeva denosumab to include the prevention of skeletal-related events in patients with multiple myeloma (MM).

FDA approved Xgeva in the same indication in January (see BioCentury, Jan. 12)...